ADIPOQ and metabolic dysfunction-associated steatohepatitis: Studies have confirmed that treatment with pioglitazone in NASH is closely associated with an increase in plasma adiponectin levels and improved insulin sensitivity in adipose tissue, liver, and skeletal muscle (Cusi, 2012).